FDA approves generic tablet for feline hyperthyroidismAugust 5, 2025The U.S. Food and Drug Administration (FDA) has approved Methimazole Coated Tablets for the treatment of feline hyperthyroidism. The product has been evaluated for safety, effectiveness, and bioequivalence to the approved reference drug.
Education Center - SponsoredVector-Borne Disease Coming to a Neighborhood Near You: Which Tests to Reach For, and Why?by • AntechWhether it’s a screening to identify exposure to tick-borne pathogens, or a broad molecular diagnostic panel to help with acute disease detection or confirm the presence of genetic material, these options empower veterinary teams, guide treatment, and support antimicrobial stewardship.
Six facts you need to know about hyperthyroidismNovember 4, 2021There are several important things a practitioner needs to know about hyperthyroidism (HT) before treatment is chosen and begun.
Zomedica announces therapeutic development milestonesDecember 13, 2017Zomedica Pharmaceuticals Corp. veterinary pharmaceutical and diagnostic company announced a development update on the company's four therapeutic candidates for use in companion animals, namely dogs and cats. ZM-012 and ZM-007: Metronidazole for acute diarrhea in dogs Development milestones for ZM-012 and ZM-007, complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs include: Finalized novel tablet formulation for ZM-012 to replace the large, bitter tasting human-approved generic tablet commonly prescribed by veterinarians for their canine patients. The beef-flavored oral tablets are intended for dogs greater than 9 pounds or 4 kilograms. Finalized the oral suspension formulation for ZM-007, which is intended for small breeds and puppies under 9 pounds or 4 kilograms. Completed pilot testing for both formulations at Michigan State University College of Veterinary Medicine to measure metronidazole's effectiveness to treat acute diarrhea in dogs. Scheduled December 2017 pre-submission meeting with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) to present the regulatory strategy and development plan for ZM-012. A safety study will commence for ZM-012 in the first half of 2018 for completion in the second half of 2018. The company also expects to hold a pre-submission …
